vs
渤健（BIIB）与Fidelity National Information Services（FIS）财务数据对比。点击上方公司名可切换其他公司
Fidelity National Information Services的季度营收约是渤健的1.2倍（$2.8B vs $2.3B），Fidelity National Information Services净利率更高（18.2% vs -2.1%，领先20.3%），Fidelity National Information Services同比增速更快（8.1% vs -7.1%），Fidelity National Information Services自由现金流更多（$739.0M vs $468.0M），过去两年Fidelity National Information Services的营收复合增速更高（6.8% vs -0.2%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
FIS是总部位于美国的跨国企业，深耕金融科技领域，提供多元金融产品及服务。该公司每年处理约750亿笔交易，支撑约9万亿美元的资金流转，为全球超过2万家客户提供服务。
BIIB vs FIS — 直观对比
营收规模更大
FIS
是对方的1.2倍
$2.3B
营收增速更快
FIS
高出15.3%
-7.1%
净利率更高
FIS
高出20.3%
-2.1%
自由现金流更多
FIS
多$271.0M
$468.0M
两年增速更快
FIS
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $2.8B |
| 净利润 | $-48.9M | $511.0M |
| 毛利率 | 78.3% | 38.3% |
| 营业利润率 | -2.5% | 18.8% |
| 净利率 | -2.1% | 18.2% |
| 营收同比 | -7.1% | 8.1% |
| 净利润同比 | -118.3% | 97.3% |
| 每股收益（稀释后） | $-0.35 | $0.98 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBFIS
| Q4 25 | $2.3B | $2.8B | ||
| Q3 25 | $2.5B | $2.7B | ||
| Q2 25 | $2.6B | $2.6B | ||
| Q1 25 | $2.4B | $2.5B | ||
| Q4 24 | $2.5B | $2.6B | ||
| Q3 24 | $2.5B | $2.6B | ||
| Q2 24 | $2.5B | $2.5B | ||
| Q1 24 | $2.3B | $2.5B |
净利润BIIBFIS
| Q4 25 | $-48.9M | $511.0M | ||
| Q3 25 | $466.5M | $264.0M | ||
| Q2 25 | $634.8M | $-470.0M | ||
| Q1 25 | $240.5M | $77.0M | ||
| Q4 24 | $266.7M | $259.0M | ||
| Q3 24 | $388.5M | $224.0M | ||
| Q2 24 | $583.6M | $243.0M | ||
| Q1 24 | $393.4M | $724.0M |
毛利率BIIBFIS
| Q4 25 | 78.3% | 38.3% | ||
| Q3 25 | 73.4% | 37.8% | ||
| Q2 25 | 77.1% | 36.4% | ||
| Q1 25 | 74.1% | 34.7% | ||
| Q4 24 | 76.2% | 36.9% | ||
| Q3 24 | 74.1% | 38.0% | ||
| Q2 24 | 77.8% | 38.2% | ||
| Q1 24 | 76.3% | 37.1% |
营业利润率BIIBFIS
| Q4 25 | -2.5% | 18.8% | ||
| Q3 25 | 22.0% | 16.8% | ||
| Q2 25 | 28.1% | 15.6% | ||
| Q1 25 | 12.8% | 13.7% | ||
| Q4 24 | 11.9% | 18.5% | ||
| Q3 24 | 18.3% | 19.1% | ||
| Q2 24 | 28.3% | 15.2% | ||
| Q1 24 | 20.3% | 14.6% |
净利率BIIBFIS
| Q4 25 | -2.1% | 18.2% | ||
| Q3 25 | 18.4% | 9.7% | ||
| Q2 25 | 24.0% | -18.0% | ||
| Q1 25 | 9.9% | 3.0% | ||
| Q4 24 | 10.9% | 10.0% | ||
| Q3 24 | 15.8% | 8.7% | ||
| Q2 24 | 23.7% | 9.8% | ||
| Q1 24 | 17.2% | 29.3% |
每股收益（稀释后）BIIBFIS
| Q4 25 | $-0.35 | $0.98 | ||
| Q3 25 | $3.17 | $0.50 | ||
| Q2 25 | $4.33 | $-0.90 | ||
| Q1 25 | $1.64 | $0.15 | ||
| Q4 24 | $1.82 | $0.51 | ||
| Q3 24 | $2.66 | $0.41 | ||
| Q2 24 | $4.00 | $0.44 | ||
| Q1 24 | $2.70 | $1.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $599.0M |
| 总债务越低越好 | $6.3B | $9.1B |
| 股东权益账面价值 | $18.3B | $13.9B |
| 总资产 | $29.4B | $33.5B |
| 负债/权益比越低杠杆越低 | 0.34× | 0.65× |
8季度趋势，按日历期对齐
现金及短期投资BIIBFIS
| Q4 25 | — | $599.0M | ||
| Q3 25 | — | $571.0M | ||
| Q2 25 | — | $581.0M | ||
| Q1 25 | — | $805.0M | ||
| Q4 24 | — | $834.0M | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $2.1B | ||
| Q1 24 | — | $3.3B |
总债务BIIBFIS
| Q4 25 | $6.3B | $9.1B | ||
| Q3 25 | $6.3B | $8.9B | ||
| Q2 25 | $6.3B | $8.9B | ||
| Q1 25 | $4.5B | $8.7B | ||
| Q4 24 | $6.3B | $9.7B | ||
| Q3 24 | $4.5B | $10.5B | ||
| Q2 24 | $6.3B | $10.6B | ||
| Q1 24 | $6.3B | $10.6B |
股东权益BIIBFIS
| Q4 25 | $18.3B | $13.9B | ||
| Q3 25 | $18.2B | $13.9B | ||
| Q2 25 | $17.6B | $14.2B | ||
| Q1 25 | $17.0B | $15.1B | ||
| Q4 24 | $16.7B | $15.7B | ||
| Q3 24 | $16.4B | $16.6B | ||
| Q2 24 | $15.9B | $17.0B | ||
| Q1 24 | $15.2B | $18.0B |
总资产BIIBFIS
| Q4 25 | $29.4B | $33.5B | ||
| Q3 25 | $29.2B | $33.0B | ||
| Q2 25 | $28.3B | $33.4B | ||
| Q1 25 | $28.0B | $32.8B | ||
| Q4 24 | $28.0B | $33.8B | ||
| Q3 24 | $28.3B | $34.3B | ||
| Q2 24 | $26.8B | $34.6B | ||
| Q1 24 | $26.6B | $35.9B |
负债/权益比BIIBFIS
| Q4 25 | 0.34× | 0.65× | ||
| Q3 25 | 0.35× | 0.64× | ||
| Q2 25 | 0.36× | 0.63× | ||
| Q1 25 | 0.27× | 0.57× | ||
| Q4 24 | 0.38× | 0.62× | ||
| Q3 24 | 0.28× | 0.63× | ||
| Q2 24 | 0.40× | 0.62× | ||
| Q1 24 | 0.41× | 0.59× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $758.0M |
| 自由现金流经营现金流 - 资本支出 | $468.0M | $739.0M |
| 自由现金流率自由现金流/营收 | 20.5% | 26.3% |
| 资本支出强度资本支出/营收 | 1.9% | 0.7% |
| 现金转化率经营现金流/净利润 | — | 1.48× |
| 过去12个月自由现金流最近4个季度 | $2.1B | $2.5B |
8季度趋势，按日历期对齐
经营现金流BIIBFIS
| Q4 25 | $511.9M | $758.0M | ||
| Q3 25 | $1.3B | $1.0B | ||
| Q2 25 | $160.9M | $382.0M | ||
| Q1 25 | $259.3M | $457.0M | ||
| Q4 24 | $760.9M | $782.0M | ||
| Q3 24 | $935.6M | $641.0M | ||
| Q2 24 | $625.8M | $546.0M | ||
| Q1 24 | $553.2M | $206.0M |
自由现金流BIIBFIS
| Q4 25 | $468.0M | $739.0M | ||
| Q3 25 | $1.2B | $952.0M | ||
| Q2 25 | $134.3M | $343.0M | ||
| Q1 25 | $222.2M | $420.0M | ||
| Q4 24 | $721.6M | $764.0M | ||
| Q3 24 | $900.6M | $605.0M | ||
| Q2 24 | $592.3M | $530.0M | ||
| Q1 24 | $507.3M | $179.0M |
自由现金流率BIIBFIS
| Q4 25 | 20.5% | 26.3% | ||
| Q3 25 | 48.4% | 35.0% | ||
| Q2 25 | 5.1% | 13.1% | ||
| Q1 25 | 9.1% | 16.6% | ||
| Q4 24 | 29.4% | 29.4% | ||
| Q3 24 | 36.5% | 23.5% | ||
| Q2 24 | 24.0% | 21.3% | ||
| Q1 24 | 22.1% | 7.3% |
资本支出强度BIIBFIS
| Q4 25 | 1.9% | 0.7% | ||
| Q3 25 | 1.8% | 2.2% | ||
| Q2 25 | 1.0% | 1.5% | ||
| Q1 25 | 1.5% | 1.5% | ||
| Q4 24 | 1.6% | 0.7% | ||
| Q3 24 | 1.4% | 1.4% | ||
| Q2 24 | 1.4% | 0.6% | ||
| Q1 24 | 2.0% | 1.1% |
现金转化率BIIBFIS
| Q4 25 | — | 1.48× | ||
| Q3 25 | 2.73× | 3.83× | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 1.08× | 5.94× | ||
| Q4 24 | 2.85× | 3.02× | ||
| Q3 24 | 2.41× | 2.86× | ||
| Q2 24 | 1.07× | 2.25× | ||
| Q1 24 | 1.41× | 0.28× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
FIS
| Banking Solutions | $1.6B | 57% |
| Other | $701.0M | 25% |
| Capital Market Solutions | $508.0M | 18% |
